A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Clinical trial NCT07393321 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07393321
Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer

Start date: 2026-02-10
Primary completion: 2028-08-31
Enrollment: 210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.